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A B S T R A C T
It has been shown that amniotic membrane transplantation (AMT) improves healing of the epithelium defects as it
serves as a basement membrane for endothelial cells growth, prevents inflammatory cell infiltration and reduces apop-
tosis in keratocytes. Having in mind the healing properties of AM we investigated the efficacy of AMT in persistent epi-
thelial defect (PED) on the corneal graft. 80 corneal grafts were prospectively followed up for presence of PED 10 months
after surgery. PED was detected in 12 cases (15%) having surgery for: rejected graft (n=4), keratoconus (n=3), kera-
toconus following PK on a second eye (n=3), corneal perforation (n=1) and Stevens-Johnson keratopathy (n=1). Epithe-
lial defect (ED) developed 14±7 days after surgery in 10 cases and 1,5 month in other two. All patients were primarily
conservatively treated with subconjuctival steroids and artificial tears for 10 days and systemic steroid therapy if needed
after, until the period of 2 weeks. 4 patients were healed. Since ED was unresponsive to all previous treatments for more
then 2 weeks, one layer of AM was placed on the corneal lesion in 5 patients, and in 3 cases of deep PED several layers of
AM were placed. Healing of the defect was obtained in 7/8 (87.5%) eyes. In 1 patient second AM transplantation was nec-
essary. Mean epithelization time was 2 weeks (range 1–3 weeks) in monolayer and 3 weeks (range 2–4 weeks) for mult-
ilayer cases. 5 out of 8 patients retained the same best corrected visual acuity (BCVA) while 3/8 patients improved their vi-
sion more than 2 lines. Preoperative corneal thickness of 255±40 mm increased to 455±90 mm. AM transplantation
facilitates healing of corneal epithelium. PED on the corneal graft unresponsive to conventional treatment can be effec-
tively cured when covered with one or more amniotic membrane layers.
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Introduction
The human amniotic membrane (AM) is the inner-
most layer of the placenta and consists of a single epithe-
lial layer, a thick basement membrane and an avascular
stroma. Due to the number of its properties, AM is in-
creasingly used in the treatment of severe ocular surface
diseases1. The amniotic basement membrane facilitates
migration and growth of epithelial cells, therefore pro-
moting epithelialization. The avascular stroma of the
AM reduces fibrovascular ingrowth and abnormal neo-
vascularization. Amniotic epithelium produces anti-in-
flammatory and growth factors beneficial to the treat-
ment of inflammatory corneal diseases2–4. Human am-
niotic membrane epithelial and mesenchymal cells ex-
press various antiangiogenic and anti-inflammatory pro-
teins such as interleukin(IL)-1 receptor antagonist and
IL-10, basic fibroblast growth factor, hepatocyte growth
factor and transforming factor b, facitilitate the migra-
tion of epithelial cells, the reinforcement of basal cellular
adhesion and the encouragement of epithelial differenti-
ation. In the successful reconstruction, the epithelial
cells are covering the amniotic membrane and conjunti-
val and corneal surfaces are stabile, wettable nonin-
flamed and free of fluorescein staining, although the ex-
act mechanism achieving these results remains unclear2.
It has been shown that amniotic membrane attracts and
traps inflammatory cells infiltrating the ocular surface,
which may explain some of its anti-inflammatory pro-
perties5. Corneal epithelium is well known for its rapid
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self-renewal process. When normal healing of corneal de-
fects is prevented, unique pathological state is mani-
fested by poor epithelisation (persistent defects or reccu-
rent erosions), chronic stromal infiltration (keratitis
accompanied by scarring), corneal vascularization and
conjunctival epithelial ingrowth onto the corneal sur-
face6–8. Numerous factors can cause these conditions,
such as malfunction of lids and tear film, damage of cor-
neal nerves, physical or chemical injuries, infections, sys-
temic disorders6,8,9, as well as disorders that can cause
scarring of the conjunctiva or persistent ocular irrita-
tion, primarily or secondary, involving the cornea6,10.
Resident corneal cells when stimulated can produce spe-
cial proteins called chemokines that can lead to the re-
cruitment of inflammatory cells into the tissue and stromal
keratocytes can transcribe and translate several chemo-
kines, such as interleukin 8, RANTES and MCP16,11,12.
Moreover, collagenases produced by keratocytes and
polymorphonuclears cause progressive corneal thinning
with potential risk of corneal perforation and loss of the
eye. In the transplant patient, this process is yet more
complicated, since in the early postoperative period, the-
re are additional insults of the relative denervation of the
cornea, poor lubrication, the instillation of frequent and
often toxic topical medications, and sometimes abnormal
lid-cornea anatomical relationship13. Punctate erosions
and vortex keratopathy, along with other types of epithe-
lial abnormalities, are common after keratoplasty, espe-
cially in the early postoperative period14,15. If not appro-
priately managed, these ubiquitous problems can esca-
late into conditions that may threaten the health of the
transplant. The critical period for stabilization of most
surface problems is in the first 3 months13. Therefore,
treatment of patients with corneal graft ulceration is
challenging and requires combining approach. AMT of-
fers the following advantages over corneal tissue use in
the treatment of persistent epithelial defects: avoidance
of potential allograft rejection and postoperative astig-
matism of tectonic corneal grafts, ease and convenience
of use, feasibility in the event of corneal tissue shortage
and preservation of a better aesthetic appearance. The
unique composition of AM seams in fact to work as a nat-
ural »healing patch« for corneal ulcers6,16,17. In this study
we wanted to determine the efficacy of amniotic mem-
brane transplantation (AMT) for the treatment of persis-
tent corneal epithelial defects (PEDs) in eyes after pene-
trating keratoplasty (PK).
Materials and Methods
80 corneal grafts were prospectively followed up for
presence of PED 10 months after surgery. PED was de-
tected in 12 cases (15%) having surgery for: rejected graft
(n=4), keratoconus (n=3), keratoconus following PK on
a second eye (n=3), corneal perforation (n=1) and Ste-
vens-Johnson keratopathy (n=1). Epithelial defect (ED)
developed 14±7 days after surgery in 10 cases and 1.5
month in other two. ED conservative treatment with
subconjuctival steroid, artificial tears and systemic ste-
roid therapy if needed was administered in all patients.
The decision for the AMT was made according to the
medical indications after the ED was unresponsive to
conservative treatment for more than 2 weeks in 8 pa-
tients. Preoperatively corneal epithelial lesions were
stained with fluorescein and photodocumented by digital
slit lamp (CSO Digital vision). Corneal thickness was
measured with non-contact optical coherence tomogra-
phy customized for the anterior segment (Zeiss Visante™
OCT) and the best corrected visual acuity (BCVA) was
determined. Amniotic membrane (one or more layers)
was placed on the corneal lesion, trimmed and sutured
with resorptive continuous suture onto the surrounding
conjuctiva. In 3 cases of deep PED several layers of AM
were placed and sutured to its uppermost layer to pre-
vent placement of sutures into cornea. Postoperatively
eyes were bandaged with contact lens and topical ste-
roid/antibiotic/artificial tears were applied. Patients were
checked on the first postoperative day and then on the
weekly basis for the epithelial size defect, corneal thick-
ness and finally BCVA after AM melting.
Amniotic membrane preparation
Amniotic membranes (AM) were obtained from the
certified eye bank (Vseobecnà fakultní nemocnice, Pra-
gue (OTB) where they were prepared under sterile condi-
tions from a human placenta shortly after elective cae-
sarean delivery. Informed consent was obtained from
each donor, and screening was made to exclude any risk
of transmissible infections such as human immunodefi-
ciency virus, hepatitis virus types B and C, and syphilis.
The AM was cut in 3 cm ´ 4 cm pieces, flattened onto in-
dividually sterilized nitrocellulose paper without folds or
tears with the epithelial surface up. Each AM was deliv-
ered in a sterile vial containing tissue culture and glyc-
erol at a ratio of 1:1in a frozen stage.Before use in the op-
erating theatre, AM was thawed by leaving the vial at
room temperature, and then the membrane is trans-
ferred to the ocular surface.
Surgical procedure
Previous to surgical procedure all patients received
subconjunctival or parabulbar anesthesia (2 mL of 2%
lidocain). In the beginning of the surgical procedure all
poorly adherent epithelium near to the lesion was re-
moved using Satin Crescent Knife in order to create the
firm base for attachment of the AM and to allow reepi-
thelisation of the membrane from neighboring healthy
corneal epithelium. In the monolayer procedure AM was
removed from the storage medium and transferred to the
recipient eye. Edges were trimmed and one layer of AM
was transferred to the recipient eye with the basement
membrane side facing up. The whole cornea and limbus
were covered without folds and tears and sutured by run-
ning 10.0 resorptive sutures (Biosorb). In the multilayer
procedure, first a large piece of AM was sutured to the
upper 2/3 of the conjunctiva covering the whole cornea,
then the stromal defect was filled with up to three layers
of AM. If the layers were stabile, additional sutures were
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not placed. In the cases of mobile multilayers, mem-
branes lying onto the PED were secured to the most up-
per layer of AM with 10.0 resorptive sutures. Minimal
number of sutures able to hold AM in place was used. Af-
ter the cavity of the deep PED was filled and good adher-
ence of the layers was secured, superficial layer of AM
was sutured in the remaining 1/3 of the circumference to
the conjunctiva with 10.0 resorptive sutures. A soft con-
tact lens is placed over the membrane at the end of the
surgery.
All surgical procedures were performed by the same
surgeon.
Results
Conservative treatment of the epithelial defect with
subconjuctival steroid/artificial tears and systemic ste-
roid therapy was obtained in 4 patients (3 keratoconus
and 1 keratoconus following PK on second eye patients).
7 out of 8 patients, unresponsive to previous conservative
therapy, obtained healing of the defect with AMT. In one
patient having previously rejected corneal graft, second
AM transplantation was necessary. In 3 cases of deep
PED (2 keratoconus patients following PK on the 2nd eye
and 1 patient with rejected graft) several layers of AM
were placed. Mean epithelization time was 2 weeks (ran-
ge 1–3 weeks) in monolayer (Figure 1) and 3 weeks
(range 2–4 weeks) for multilayer cases. Epithelial defects
situated peripheraly on the cornea healed faster. Five out
of eight patients retained the same BCVA while 3/8 pa-
tients improved their vision more than 2 lines (2 kera-
toconus patients and 1 with previously rejected corneal
graft). Mean preoperative corneal thickness of 255±40
mm increased to 455±90 mm in cases with deep PED (Fig-
ure 2).
Discussion
Amniotic membrane transplantation has gained
widespread attention as an effective method of recon-
struction of the ocular surface, having a unique combina-
tion of properties, including the facilitation of migration
of epithelial cells, the reinforcement of basal cellular ad-
hesion and the encouragement of epithelial differentia-
tion. Its ability to modulate stromal scarring and its
anti-inflammatory activity has led to its use in the treat-
ment of ocular surface pathology. Amniotic membrane
transplantation has been used for reconstruction of the
corneal surface in the setting of persistent epithelial de-
fects, partial limbal stem cell deficiency, bullous kera-
topathy and corneoscleral ulcers. It has also been used in
conjunction with limbal stem cell transplantation for to-
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Fig. 1. A. Epithelial defect on the corneal graft before AMT, B. Monolayer AMT placed on the epithelial defect of the corneal graft, the
border of AM indicated by arrows. AM-amniotic membrane, AMT-amniotic membrane transplantation. (jpg files)
Fig. 2. A. Visante OCT preoperative corneal thickness with deep PED, B. Visante OCT postoperative corneal thickness with deep PED.
Visante OCT-optical coherence tomography customized for the anterior segment, PED-persistent epithelial defect. (jpg files)
tal limbal stem cell deficiency18. In persistent epithelial
corneal defects, AM serves to provide a basement mem-
brane substrate for the migration and adhesion of epi-
thelial cells when used as an inlay graft. When used as an
overlay patch it facilitates epithelialization by providing
a barrier against inflammatory cells and mediators. The
AM, being continuously moistened by tears, provides ad-
equate hydration to the regenerating epithelium and
protects it from the abrasive effect of an abnormal pal-
pebral conjunctiva19. The amniotic membrane stromal
matrix has a direct anti-scarring effect as evidenced by
its suppression of TGF- signalling and myofibroblast
differentiation, helps re-establish a microenvironmental
niche that is conducive for the growth of epithelial pro-
genitor cells.Finally, the amniotic membrane may pro-
mote nerve regeneration by maintaining nerve growth
factor (NGF) signaling20. Amniotic membrane transplan-
tation may be considered an alternative method for trea-
ting PEDs that are refractory to conventional treat-
ment21. In our study we wanted to determine AM healing
effects on the epithelial defects of corneal grafts. PED de-
veloped in 15% of all transplants in average of 10 days af-
ter surgery with exception of the two later cases where it
developed after 1,5 month. Four patients had previously
rejected corneal grafts, and three had keratoconus with a
corneal graft on the other eye. The remaining others had
epithelial defects on the keratoconus cornea, one had cor-
neal perforation and one Stevens-Johnson syndrome. In
4 patients conservative treatment of ED with subconjuc-
tival steroid/artificial tears, therapeutic contact lens and
systemic steroid therapy was effective. In the other 8 pa-
tients conservative therapy failed and AMT (5 monolayer
and 3 multilayer) was performed after two weeks. ED
healed in average in 2 weeks (range 1–3 weeks) in mono-
layer and in 3 weeks (range 2–4 weeks) for multilayer
cases. In patient who had previously rejected corneal
graft we had to perform second AMT transplantation.
Patients with keratoconus and peripheral lesions healed
faster than the others. Patients who had previously
transplanted and rejected graft and also the patients who
had previously transplanted the other keratoconus eye
had deep PED and several layers of AM were sutured.
Their visual acuity improved for two lines after the sur-
gery. In these cases the use of multilayer AM can indeed
reinforce the healing effect of AM probably by amplifying
the concetration of useful factors secreted from the stro-
ma. In one patient with Stevens-Johnson syndrome
(SJS) AMT very successfully healed ED and improved
BCVA. AMT is established method of therapy for SJS
and can avert the catastrophic ophthalmic sequelae of
this rare but devastating disease22–24. Corneal thickness
of patients with deep PED was thicker for 200 mm in av-
erage as compared to before AMT. Persistent epithelial
defects can compromise ocular surfaces and deplete the
stem-cell population that repairs the damaged corneal
epithelium, leading to pain, scarring, vascularization,
and loss of sight. Their treatment includes: elimination
of underlying problems, control of inflammation, preven-
tion of additional loss of tissue, protection of ocular sur-
faces with a bandage contact lens and possible surgery or
corneal transplant. When medical therapies fail, the type
of surgery (e.g., ocular surface reconstruction) indicated
is dependent upon the »extent of involvement of the cor-
nea (e.g., epithelium, basement membrane or stroma),
extent of limbal ischemia, conjunctival necrosis and in-
tact tear supply«25,26. Amniotic membrane (AM), the in-
nermost layer of the fetal membrane, exhibits properties
that are helpful in wound healing, particularly of ocular
injuries and has been proposed for various clinical indica-
tions for ocular reconstruction. We conclude that persis-
tent epithelial defects on the corneal graft unresponsive
to conventional treatment can be effectively cured when
covered with one or more amniotic membrane layers.
Abbreviations: AMT – Amniotic membrane trans-
plantation, AM – Amniotic membrane, PED – persistent
epithelial defect, ED – Epithelial defect, BCVA – best cor-
rected visual acuity
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TRANSPLANTACIJA AMNIJSKE MEMBRANE U LIJE^ENJU PERZISTENTNIH EPITELNIH
EROZIJA RO@NI^NOG TRANSPLANTATA
S A @ E T A K
Istra`ivanje su pokazala da transplantacija amnijske membrane (TAM) pobolj{ava cijeljenje epitelnih defekata tako
da slu`i kao bazalna membrana za rast endotelnih stanica, spe~ava infiltraciju upalnih stanica i smanjuje apoptozu u
keratocitima. Imaju}i na umu cijelje}e u~inke amnijske membrane (AM) istra`ivali smo uspje{nost TAM u perzistent-
nim ne-cijelje}im defektima (PND) ro`ni~nih transplantata. Osamdeset pacijenata prospektivno je pra}eno u razdoblju
od 10 mjeseci nakon operacije. PND je imalo 12 pacijenata (15%) koji su imali transplantaciju ro`nice zbog: prethodno
odba~enog transplantata (n=4), keratokonusa (n=3), transplantacije na drugom oku zbog keratokonusa (n=3), puknu-
}a ro`nice (n=1) i Stevens-Johnsonova sindroma (n=1). Epitelni defekt (ED) se pojavio 14±7 dana nakon operacije u
10 pacijenata a 1.5 mjeseci nakon operacije u preostala dva. Svi su pacijenti primarno lije~eni konzervativno kortiko-
steroidnim subkonjunktivalnim injekcijama i umjetnim suzama kroz 10 dana i po potrebi sistemskom steroidnom tera-
pijom u trajanju do 2 tjedna. U ~etiri pacijenta ED je zacijelio na lokalnu terapiju. U 5 pacijenata kod kojih ED nije
cijelio na odgovaraju}u terapiju vi{e od 2 tjedna jedan sloj amnijske membrane je transplantiran na defekt ro`nice, a u 3
pacijenta koja su imala duboki ED vi{eslojna amnijska membrana je stavljena. Cijeljene defekta je nastalo u 7/8 (87,5%)
pacijenata. U jednog pacijenta bila je potrebna druga TAM. Prosje~no vrijeme epitelizacije bilo je 2 tjedna (1–3 tjedna)
kod tranplantacije jednog sloja AM dok je u vi{eslojne iznosilo 3 tjedna (2–4 tjedna). U pet od osam pacijenata vidna
o{trina ostala je jednaka kao prije transplantacije dok se u 3/8 pacijenata vidna o{trina popravila za vi{e od dva reda na
Snelenovim tablicama. Preoperativna debljina ro`nice od 255±40 mm porasla je na 455±90 mm. Transplantacija AM
poma`e cijeljenju epitela ro`nice. Duboki epitelni defekt transplantata koji ne cijeli na standardnu terapiju mo`e se
uspje{no lije~iti tranplantacijom jednog ili vi{e slojeva amnijske membrane.
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